Rutgers cancer Institute of NJ is a clinical research site located in New Brunswick, New Jersey, United States 08853.
Crixeo Health Trust Score: 63/100 (FAIR). This profile has not yet been claimed by the site owner.
Rutgers cancer Institute of NJ has participated in 3 clinical trials.
Therapeutic areas: Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma.
Sponsors: Eisai Inc..
Trust Score: 63/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Rutgers cancer Institute of NJ has a Crixeo Trust Score of 63/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Rutgers cancer Institute of NJ has 3 clinical trials on record. Their work covers Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma.
Rutgers cancer Institute of NJ has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.